cisplatin, nivolumab
Nivolumab in combination with cisplatin and gemcitabine is approved by the USFDA for unresectable or metastatic urothelial carcinoma
March 2024: The Food and Drug Administration has granted approval for the use of nivolumab (Opdivo, Bristol-Myers Squibb Company) in conjunction with cisplatin and gemcitabine as the initial treatment for adult patients with unres..
Erdafitinib is approved by USFDA for locally advanced or metastatic urothelial carcinoma
Erdafitinib (Balversa, Janssen Biotech) was approved by the Food and Drug Administration on January 19, 2024, for adult patients with FGFR3 genetic changes who have locally advanced or metastatic urothelial carcinoma (mUC). Patie..
Enfortumab vedotin-ejfv with pembrolizumab is approved by USFDA for locally advanced or metastatic urothelial cancer
As of December 15, 2023, the Food and Drug Administration (FDA) approved enfortumab vedotin-ejfv (Padcev, Astellas Pharma) along with pembrolizumab (Keytruda, Merck) for people who have locally advanced or metastatic urothelial c..
Pembrolizumab, USFDA
Enfortumab vedotin-ejfv with pembrolizumab is approved by USFDA for locally advanced or metastatic urothelial carcinoma
Feb 2024: The Food and Drug Administration has sped up the approval process for two drugs, enfortumab vedotin-ejfv (Padcev, Astellas Pharma) and pembrolizumab (Keytruda, Merck). These drugs are meant to treat people with locally ..
Bristol Myers Squibb, CHECKMATE-274, nivolumab, Opdivo, Urothelial carcinoma
Nivolumab has been approved by the FDA for use as an adjuvant treatment for urothelial carcinoma
August 2021: Nivolumab (Opdivo, Bristol-Myers Squibb Co.) has been approved by the Food and Drug Administration for the adjuvant treatment of patients with urothelial carcinoma (UC) who are at high risk of recurrence following rad..
Astellas Pharma US, NCT03474107, Padcev, Trial EV-301
The FDA has given enfortumab vedotin-ejfv approval for the treatment of locally advanced or metastatic urothelial carcinoma
August 2021: Enfortumab vedotin-ejfv (Padcev, Astellas Pharma US, Inc.), a Nectin-4-directed antibody and microtubule inhibitor combination, has been approved by the Food and Drug Administration for adult patients with locally adv..
Immunomedics Inc, mUC, platinum-containing chemotherapy, programmed death receptor-1, sacituzumab govitecan, Trodelvy, TROPHY
Sacituzumab govitecan receives fast approval from the FDA for advanced urothelial cancer
August 2021: Sacituzumab govitecan (Trodelvy, Immunomedics Inc.) was given accelerated approval by the Food and Drug Administration for patients with locally advanced or metastatic urothelial cancer (mUC) who had previously receiv..